文章基本信息

标题：We should stop calling hysteroscopic tissue removal systems ‘morcellators’ FVVinObGyn-13-191
本地全文：下载
作者：E. Saridogan
期刊名称：Facts, Views & Vision in ObGyn
印刷版ISSN：2032-0418
出版年度：2021
卷号：13
期号：3
DOI：10.52054/FVVO.13.3.036
语种：English
出版社：Universa Press
摘要：The United Kingdom National Institute for Health and Care Excellence (NICE) released its guidance on ‘Hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids on 25 August 2021 (National Institute for Health and Care Excellence, 2021a). It concluded that evidence on the safety of hysteroscopic mechanical tissue removal (hysteroscopic morcellation) for uterine fibroids showed there were well recognised, infrequent but potentially serious side-effects. It stated that evidence on its efficacy was lim- ited in quantity and quality and that this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. This means that clinicians using the procedure should collect data, for example by audit or research, and that risk of serious harm needs to be explained to the patient before they make a decision. It also requires that the clinical governance lead in their organisation is informed when this service is provided.